Toll-like receptor ligands energize peptide vaccines through multiple paths
E Celis - Cancer Research, 2007 - AACR
E Celis
Cancer Research, 2007•AACRThe potential of vaccines for cancer therapy or prevention has yet to be realized. Recently,
we showed that using an immunologic adjuvant composed of a Toll-like receptor (TLR)
ligand can increase the production of antitumor CTLs produced by a peptide vaccine in a
mouse model of breast cancer. By increasing the cross talk between the innate and adaptive
immune systems, TLR ligands can drive expansion and memory of CTLs that can destroy
cancer cells.[Cancer Res 2007; 67 (17): 7945–7]
we showed that using an immunologic adjuvant composed of a Toll-like receptor (TLR)
ligand can increase the production of antitumor CTLs produced by a peptide vaccine in a
mouse model of breast cancer. By increasing the cross talk between the innate and adaptive
immune systems, TLR ligands can drive expansion and memory of CTLs that can destroy
cancer cells.[Cancer Res 2007; 67 (17): 7945–7]
Abstract
The potential of vaccines for cancer therapy or prevention has yet to be realized. Recently, we showed that using an immunologic adjuvant composed of a Toll-like receptor (TLR) ligand can increase the production of antitumor CTLs produced by a peptide vaccine in a mouse model of breast cancer. By increasing the cross talk between the innate and adaptive immune systems, TLR ligands can drive expansion and memory of CTLs that can destroy cancer cells. [Cancer Res 2007;67(17):7945–7]
AACR